Trial reportPloS one2014
Changes in QTc interval in the citalopram for agitation in Alzheimer's disease (CitAD) randomized trial.
Trial report in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00898807 (A Multi-Center Randomized Placebo-Controlled Clinical Trial Study of Citalopram for the Treatment of Agitation in Alzheimer's Disease), which is not on this map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multi-Center Randomized Placebo-Controlled Clinical Trial Study of Citalopram for the Treatment of Agitation in Alzheimer's Disease
Who cites it
24 citing papers in PubMed, 59 citations in OpenAlex.
- Antidepressant Augmentation versus Switch in Treatment-Resistant Geriatric Depression.The New England journal of medicine · 2023Trial
- Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer's Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial.The American journal of psychiatry · 2016Trial
- Citalopram, methylphenidate, or their combination in geriatric depression: a randomized, double-blind, placebo-controlled trial.The American journal of psychiatry · 2015Trial
- The Effect of Venlafaxine on Electrocardiogram Intervals During Treatment for Depression in Older Adults.Journal of clinical psychopharmacologyTrial
- The Effect of Agomelatine in Behavioral and Psychological Symptoms of Dementia.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2022Article
- Association Between the Cholinesterase Inhibitor Donepezil and the Cholinergic Precursor Choline Alphoscerate in the Treatment of Depression in Patients with Alzheimer's Disease.Journal of Alzheimer's disease reports · 2022Article
- Diagnosis and Treatment of Alzheimer's Disease:: An Update.Delaware journal of public health · 2021Article
- Psychotropic Medication and Cognitive, Functional, and Neuropsychiatric Outcomes in Alzheimer's Disease (AD).Journal of the American Geriatrics Society · 2021Observational
- Article
- Considerations and Current Trends in the Management of the Geriatric Patient on a Consultation-Liaison Service.Current psychiatry reports · 2020Review
- Agitation and impulsivity in mid and late life as possible risk markers for incident dementia.Alzheimer's & dementia (New York, N. Y.) · 2020Review
- Effects of antidepressants on QT interval in people with mental disorders.Archives of medical science : AMS · 2020Review
- Novel deep learning model for more accurate prediction of drug-drug interaction effects.BMC bioinformatics · 2019Article
- A review of citalopram dose restrictions in the treatment of neuropsychiatric disorders in older adults.The mental health clinician · 2019Article
- Pharmacologic management of behavioral and psychological symptoms of major neurocognitive disorder.The mental health clinician · 2018Article
- Evaluating the risk of QTc prolongation associated with antidepressant use in older adults: a review of the evidence.Therapeutic advances in drug safety · 2018Review
- Monitoring of somatic parameters at outpatient departments for mood and anxiety disorders.PloS one · 2018Article
- Dementia-related agitation: a review of non-pharmacological interventions and analysis of risks and benefits of pharmacotherapy.Translational psychiatry · 2017Review
- Characterizing Highly Benefited Patients in Randomized Clinical Trials.The international journal of biostatistics · 2017Article
- A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer's disease patients with agitation.Journal of pharmacokinetics and pharmacodynamics · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 10 institutions in 2 countries.
Funding
Abstract
backgroundA Food and Drug Administration (FDA) safety communication in August 2011 warned that citalopram was associated with a dose dependent risk of QT prolongation and recommended dose restriction in patients over the age of 60 but did not provide data for this age group.
methodsCitAD was a randomized, double-masked, placebo-controlled, multicenter clinical trial for agitation in Alzheimer's disease (AD). Participants were assigned to citalopram (target dose of 30 mg/day) or placebo in a 1 ∶ 1 ratio. 186 people, 181 of whom were over the age of 60, having probable AD with clinically significant agitation were recruited from September 2009 to January 2013. After the FDA safety communication about citalopram, ECG was added to the required study procedures before enrollment and repeated at week 3 to monitor change in QTc interval. Forty-eight participants were enrolled after enhanced monitoring began.
resultsCitalopram treatment was associated with a larger increase in QTc interval than placebo (difference in week 3 QTc adjusting for baseline QTc: 18.1 ms [95% CI: 6.1, 30.1]; p = 0.004). More participants in the citalopram group had an increase ≥ 30 ms from baseline to week 3 (7 in citalopram versus 1 in placebo; Fisher's exact p = 0.046), but only slightly more in the citalopram group met a gender-specific threshold for prolonged QTc (450 ms for males; 470 ms for females) at any point during follow-up (3 in citalopram versus 1 in placebo, Fisher's exact p = 0.611). One of the citalopram participants who developed prolonged QTc also displayed ventricular bigeminy. No participants in either group had a cardiovascular-related death.
conclusionCitalopram at 30 mg/day was associated with improvement in agitation in patients with AD but was also associated with QT prolongation.
trial registrationClinicalTrials.gov NCT00898807.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.